Sort   by:  
 Page size 
TranscriptomicsGene exprssion profile classification predicts clinical outcome in juvenile myelomonocytic leukemia
Gene expression analysis identified a specific signature of differentially expressed genes discriminating good and poor responders in JMML patients. Gene expression signatures were analyzed on two EWOG patient cohorts of pediatric JMML patients. Keywords: Expression data Class comparison between AM...
ORGANISM(S): Homo sapiens 
2009-12-31 | E-GEOD-14858 | biostudies-arrayexpress
GenomicsGenome-wide DNA Methylation is Predictive of Outcome in Juvenile Myelomonocytic Leukemia
Juvenile myelomonocytic leukemia (JMML) is a myeloproliferative disorder of childhood caused by mutations in the Ras pathway. Outcomes in this disease vary dramatically from spontaneous resolution with little or no treatment to rapid relapse after hematopoietic stem cell transplantation. Given the h...
EGAS00001002700 | EGA
ProteomicsOncogenic and microenvironmental signals drive cell type-specific apoptosis resistance in juvenile myelomonocytic leukemia
Juvenile myelomonocytic leukemia (JMML) is caused by constitutively activated RAS signalling and is characterized by increased proliferation and predominant myelomonocytic differentiation of hematopoietic cells. Using Mx-Cre;PTPN11D61Y mice, which reflect human JMML, we show that RAS pathway activat...
ORGANISM(S): Mus musculus (Mouse) 
2025-05-07 | PXD055845 | Pride
Ptpn11 Bcl2 Jmml Apoptosis Bcl-xl Juvenile monocytic leukemia Mcl-1 Extrinsic and intrinsic shp2 signalling Shp2 
GenomicThe Genomic Landscape of Juvenile Myelomonocytic Leukemia

This study analyzed samples from 29 patients with juvenile myelomonocytic leukemia (JMML) using whole exome sequencing. Each patient had a paired germline tissue along with a diagnostic leukemia sample. Germline tissue types included buccal mucosa, cordblood, Epstein-Barr virus immortalized cell ...

phs000973 | dbGaP
TranscriptomicsEffective requesting method to detect fusion transcripts in chronic myelomonocytic leukemia RNA-seq
Two sets of 10 samples from patients with CMML were used for this study. The first set (CMML11 to CMML20) includes 10 blood samples supplied by Eric Jourdan (Biological Resource Center CHU-Nimes, France). Peripheral blood mononuclear cells were separated by Ficoll-Hypaque density gradient and preser...
ORGANISM(S): Homo sapiens 
2025-07-22 | E-MTAB-13763 | biostudies-arrayexpress
TranscriptomicsTranscriptional profiling of the MV4-11 cell line treated with trabectidin or azacitidin
In order to study the effects of trabectedin in chronic myelomonocytic leukemia and in juvenile myelomonocytic leukemia, we performed whole genome transcriptional profiling of a model cell line treated under either the reference drug for CMML / JMML (Azacitidine) or trabectedin.
ORGANISM(S): Homo sapiens 
2016-12-14 | E-MTAB-2978 | biostudies-arrayexpress
ProteomicsDiscovery and development of CLL-1 as a cellular immunotherapy target in juvenile myelomonocytic leukemia
Juvenile myelomonocytic leukemia (JMML) is an aggressive hematologic malignancy with myeloproliferative characteristics that affects young children and is associated with significant morbidity and mortality. Leukemia stem cells (LSCs) have been shown to drive relapse and progression in JMML and incl...
ORGANISM(S): Homo sapiens (Human) 
2025-02-03 | PXD052910 | Pride
Jmml Surfaceomics Car-t cell Immunotherapy 
TranscriptomicsTET2 mutations are associated with specific methylation profiles in patients with Chronic Myelomonocytic Leukemia
Chronic myelomonocytic leukemia (CMML) has recently been associated with a high incidence of diverse mutations in genes implicated in epigenetic mechanisms such as TET2 or EZH2. We have performed genome-wide methylation arrays and mutational analysis of TET2, IDH1, IDH2, EZH2 and JAK2 in a group of ...
ORGANISM(S): Homo sapiens 
2012-02-13 | E-GEOD-31600 | biostudies-arrayexpress
GenomicsChronic myelomonocytic leukemia
Chronic myelomonocytic leukemia is an aggressive hematological malignancy with dismal outcomes, with the pCMML subtype in particular having median OS of <2 years and high rates of AML transformation (Patnaik et al., 2014). Given limited therapeutic options for affected patients, we carried out this ...
EGAS00001005107 | EGA
GenomicsCell type-specific apoptosis resistance in juvenile myelomonocytic leukemia
Cell type-specific apoptosis resistance in juvenile myelomonocytic leukemia
PRJNA1163322 | ENA
Sort   by:  
 Page size